Search clinical trials for: Active Hydromorphone PR Active Naloxone PR

Total 178 results

Mundipharma Research GmbH & Co KG

Completed

Optimisation of Hydromorphone - Naloxone Ratio for the Treatment of Pain (HMX3501)

Constipation

Romania, Switzerland, Israel, Belgium, Germany, Australia, Austria, Czech Republic, Denmark, Finland, France, Netherlands, Poland, United Kingdom
Fondazione Salvatore Maugeri

Completed

Osteopathy in Chronic Obstructive Pulmonary Disease (COPD) Rehabilitation Trial

Chronic Obstructive Pulmonary Disease

Italy
Develco Pharma Schweiz AG

Unknown

Naloxone HCl PR Tablets in Patients With Opioid Induced Constipation (Naxos)

Opioid-Induced Constipation

United Kingdom, Bulgaria, Czechia, Germany, Poland, Portugal, Serbia, Slovakia, Spain
UCB Pharma
Otsuka Pharmaceutical Co., Ltd.

Completed

Bioequivalence Study of Rotigotine Transdermal Patch With Two Different Formulations in Healthy Japanese Subjects

Healthy Volunteers

Germany
Mundipharma (China) Pharmaceutical Co. Ltd

Completed

Determine the Safety and Efficacy of Oxy/Nal Tablets Compared to Oxy PR in Subjects With Cancer Pain

Pain | Cancer

China
Mundipharma SAS

Terminated

Efficacy of Oxycodone/Naloxone(OXN), Versus Oxycodone (OXY), for the Reduction of Intensity of Opioid-induced Constipation in Pain Patients (OXN3505)

Pain | Constipation

France
Seoul National University Hospital
Kuhnil Pharmaceutical Co., Ltd.

Unknown

Efficacy and Safety of Melatonin PR and Clonazepam in Patients With REM Sleep Behavior Disorder in Parkinson Disease

Parkinson Disease | REM Sleep Behavior Disorder

Korea, Republic of
UCB BIOSCIENCES GmbH
Pharmaceutical Health Sciences; Bracket Global

Completed

A Study to Compare the Adhesiveness of 2 Different Rotigotine Patches Used for the Treatment of Parkinson's Disease

Parkinson's Disease

Germany
Mundipharma Research GmbH & Co KG

Completed

Oxycodone/Naloxone Prolonged Release (OXN PR) Compared to Placebo to Demonstrate Improvement in Symptoms of Restless Legs Syndrome (RLS) in Subjects With Moderate to Severe Idiopathic RLS With Daytime Symptoms

Moderate to Severe Idiopathic RLS With Daytime Symptoms

Spain, Sweden, Germany
Pfizer

Completed

A Study To Find Out How Fesoterodine Works In Children Aged 6 To 17 Years With Bladder Overactivity Caused By A Neurological Condition

Urinary Bladder, Neurogenic

France, United States, Spain, Korea, Republic of, United Kingdom, Malaysia, Taiwan, Finland, Japan, Lithuania, Italy, Turkey, Estonia, Slovakia, Belgium, Canada, Germany, Greece, India, Philippines, Poland, Russian Federation, South... and more
Mundipharma Research GmbH & Co KG

Completed

A Study to Demonstrate Improvement in Symptoms of Constipation in Subjects That Require Around-the-clock Opioid Pain Killer Therapy

Pain | Constipation

United Kingdom
GlaxoSmithKline

Completed

Clinical Evaluation of Ropinirole Prolonged Release/Extended Release (PR/XR) Tablet for Adjunctive Therapy to L-dopa in Subjects With Advanced Parkinson's Disease

Parkinson Disease

Japan
Biogen

Completed

Exploratory Study to Assess the Effect of Fampridine (BIIB041) on Walking Ability and Balance in Participants With Multiple Sclerosis. (MOBILE)

Multiple Sclerosis

Sweden, United Kingdom, Netherlands, Belgium, Canada, Italy
Mundipharma Oy

Completed

OXN PR Compared to OXY PR in Subjects With Postoperative Pain After Knee Arthroplasty (OXN4505)

Post Operative Pain

Finland
Pfizer

Completed

Open-label Long-term Extension Study of Fesoterodine in Japanese Subjects With Neurogenic Detrusor Overactivity.

Urinary Bladder, Neurogenic

Japan
Rajesh Pahwa, MD
GlaxoSmithKline

Completed

Pramipexole Conversion to Ropinirole Controlled Release (CR)

Parkinson Disease

United States
Tesaro, Inc.
Myriad Genetics, Inc.; Facing Our Risk of Cancer Empowered

Completed

A Study of Niraparib in Patients With Ovarian Cancer Who Have Received Three or Four Previous Chemotherapy Regimens (QUADRA)

Ovarian Neoplasms | Ovarian Cancer

United States, Canada
University of Southern California

Not yet recruiting

Ketamine HCl Prolonged Release Oral Tablets for CRPS

Complex Regional Pain Syndromes

United States
Janssen-Cilag International NV

Completed

Open Label, Multicentre Extension Study of Protocol 42603ATT3002 to Evaluate Safety of Prolonged Release OROS Methlyphenidate in Adults With Attention Deficit Hyperactivity Disorder (ADHD)

Attention Deficit Disorder With Hyperactivity

France, Germany, Spain, Switzerland, Netherlands, Portugal, Norway
Janssen-Cilag International NV

Completed

A Study to Evaluate Effectiveness and Safety of Prolonged Release OROS Methylphenidate in Adults With Attention Deficit Hyperactivity Disorder

Attention Deficit/ Hyperactivity Disorder

France, Belgium, Germany, Spain, Switzerland, Denmark, Finland, Netherlands, Norway, Sweden, United Kingdom
Institut Paoli-Calmettes
GlaxoSmithKline

Not yet recruiting

A Phase 1b/2 Trial Evaluating Safety and Efficacy of CAPecitabine in Combination With Ni-rapaRIb in HER2-negative Advanced Breast canCEr (CAPRICE)

Breast Cancer
Loyola University
University of Illinois at Chicago; University of Ibadan

Completed

Risk Clinical Stratification of Sickle Cell Disease in Nigeria, Assessment of Efficacy/Safety of Hydroxyurea Treatment

Sickle Cell Disease | Sickle Cell Anemia

Nigeria
AGO Research GmbH
GlaxoSmithKline

Not yet recruiting

Study to Estimate Efficacy of Combining Dostarlimab and Niraparib in Relapsed EOC After Treatment With PARPi

Primary Peritoneal Cancer | Recurrent Ovarian Cancer | Recurrent Fallopian Tube Cancer
University of Rochester
Massey Cancer Center

Completed

Study of Carfilzomib and Vorinostat for Relapsed or Refractory Lymphoma

Lymphoma

United States
University Hospital, Toulouse

Completed

Effects of PR Oxycodone and of Levodopa, vs Placebo, on Central Neuropathic Pain in Parkinson's Disease (OXYDOPA)

Parkinson Disease

France
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Panobinostat and Carfilzomib in Treating Participants With Relapsed or Refractory Multiple Myeloma

Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma | Non-Secretory Plasma Cell Myeloma | Plasmacytosis

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Effect of Opioid Infusion Rate on Abuse Liability Potential of Intravenous Hydromorphone for Cancer Pain

Hematopoietic and Lymphoid Cell Neoplasm | Malignant Solid Neoplasm

United States
Peking University Cancer Hospital & Institute

Active, not recruiting

PSMA Specific [68Ga]-P137 Peptide Probe for PET Imaging in Prostate Cancer

Prostate Cancer

China
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Filanesib and Carfilzomib in Treating Patients With Relapsed or Refractory Multiple Myeloma or Plasma Cell Leukemia

Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma | Plasma Cell Leukemia

United States
Anesthesia Research Group UA

Completed

Vasopressor Requirements Depends on Sedation Strategy

Respiratory Complication | Hemodynamic Instability | Sedation Complication | Agitation on Recovery From Sedation | Sedative Adverse Reaction

Ukraine
Biogen
Acorda Therapeutics

Completed

A Pharmacokinetics (PK) and Safety Study of Oral Fampridine-PR 10 mg in Chinese, Japanese, and Caucasian Adult Healthy Volunteers

Healthy

Hong Kong, Australia
GlaxoSmithKline

Completed

Open-Label Extension Study With REQUIP PR for Subjects From Study ROP111528

Parkinson Disease

China
Amgen

Completed

Phase 1b/2 Study of Carfilzomib, Carboplatin, and Etoposide in Patients With Previously Untreated Extensive Stage Small-cell Lung Cancer

Extensive-Stage Small-Cell Lung Cancer

Canada, United States, Russian Federation
GlaxoSmithKline

Completed

A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel Group Study of Six Months Treatment With Ropinirole PR as Adjunctive Therapy in Patients With Parkinson's Disease Who Are Not Optimally Controlled on L-Dopa

Parkinson Disease

China
Suzhou Genhouse Bio Co., Ltd.

Recruiting

A Phase Ib/II Clinical Study of GH21 Capsules Combined With Osimertinib Mesylate Tablets in Patients With NSCLC

Non-Small Cell Lung Cancer With EGFR Mutation

China
Biogen
Acorda Therapeutics

Completed

Open Label Extension Study to Evaluate the Safety and Tolerability of Oral Fampridine-Sustained Release (SR) in Canadian Participants With Multiple Sclerosis Who Participated in Acorda Extension Trials.

Multiple Sclerosis

Canada
Ferrer Internacional S.A.

Terminated

Single Dose Study to Compare the Pharmacodynamics of Torasemide-PR 10 mg,Torasemide-IR 10 mg and Furosemide-IR 40 mg in Patients With Compensated Heart Failure

Compensated Heart Failure

Spain
Seoul National University Hospital

Unknown

Mirabegron for Treatment of Overactive Bladder Symptoms in Patients With Parkinson's Disease

Overactive Bladder | Parkinson Disease

Korea, Republic of
Qilu Pharmaceutical Co., Ltd.

Not yet recruiting

Meropenem-FL058 Phase 2 Study in the Treatment of Complicated Urinary Tract Infections

Acute Pyelonephritis | Complicated Urinary Tract Infection
Beijing Ditan Hospital

Unknown

An Observational Cohort Study of Clinical Outcomes After Antiviral Treatment of Chronic Hepatitis C

Chronic Hepatitis C

China
CHU de Quebec-Universite Laval
Fédération des médecins résidents du Québec

Not yet recruiting

Prophylactic Use of Tamsulosin in the Prevention of Post-operative Urinary Retention in Men After Rectum Resection (R-POUR)

Colorectal Surgery | Urinary Retention | Post-operative Urinary Retention | Rectal Resection | Tamsulosin

Canada
Psychiatry Karolinska
Region Stockholm; Ministry of Health and Social Affairs, Sweden

Completed

Efficacy and Effectiveness of Methylphenidate in Swedish Male Prison Inmates With Attention-deficit Hyperactivity Disorder (ADHD)

Attention Deficit Hyperactivity Disorder

Sweden
Pfizer

Completed

A Study to Evaluate the Efficacy of Tolterodine Prolonged Release Compared With Propiverine for the Treatment of Korean Patients With Overactive Bladder as Assessed by Ambulatory Urodynamic Monitoring

Urinary Bladder, Overactive

Korea, Republic of
Korea University Ansan Hospital

Not yet recruiting

Postoperative Sugammadex After COVID-19

COVID-19 | General Anesthesia
Allergan

Completed

A Study To Assess the Safety and Effects of OnabotulinumtoxinA (BOTOX) Intramuscular Injection in Adult Participants With Moderate to Severe Platysma Prominence

Platysma Prominence

United States, Canada
Allergan

Completed

A Study to the Assess the Change in Condition and Adverse Events of OnabotulinumtoxinA X Injection in Adult Participants With Glabellar Lines

Glabellar Lines

United States
IRCCS San Raffaele
Menarini International Operations Luxembourg SA

Completed

Effects of Ranolazine on Coronary Microvascular Dysfunction in Patients With Hypertrophic Cardiomyopathy

HCM - Hypertrophic Non-Obstructive Cardiomyopathy

Italy
Onze Lieve Vrouw Hospital
Universiteit Antwerpen; MSD Belgium BVBA

Completed

Functional Respiratory Imaging After Neostigmine or Sugammadex (FRINeoS)

Respiratory-Gated Imaging Techniques

Belgium
University of Jena
German Federal Ministry of Education and Research

Completed

Intervention With Lupin Protein-enriched Foods in Hypercholesterolemic Subjects

Hypercholesterolemia

Germany
Guangzhou Medical University

Recruiting

Intra-pemetrexed Plus Third-generation Small Molecule TKI Drugs (e.g. 'Osimertinib') Versus Third-generation Small Molecule TKI Drugs Alone for Leptomeningeal Metastasis From Epidermal Growth Factor Receptor Mutation-Positive Non-Small-cell Lung Cancer

Leptomeningeal Metastasis

China

3

Subscribe